- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination with Pembrolizumab in Patients with Percutaneously Accessible Lesions with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy
This study looks at a new treatment for advanced melanoma that has not responded to previous immunotherapy. It combines an injected drug (LTX-315) with an existing cancer drug (Pembrolizumab) to see if it can shrink tumours and extend life. Researchers will closely monitor participants' health.
For: Advanced MelanomaFrance · Norway · Spain - AuthorisedTherapeutic exploratory (Phase II)
Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts
This study is looking at a new way to treat prostate cancer that has spread. It compares two different drug combinations to see which is better at stopping the cancer from growing for at least four months.
For: prostate cancerItaly